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Background and Aims: Nosocomial transmission of blood-borne pathogens is common in a dialysis setting. Hepatitis C 
virus (HCV) infection is a common problem that increases morbidity and mortality in hemodialysis patients. Blood 
transfusion and the duration of hemodialysis are the most important factors in HCV transmission. The aim of the study 
was to determine the incidence rate of HCV antibody in hemodialysis patients and its association with some factors. 
Methods: In this descriptive-analytical study, HCV antibody was measured in 93 hemodialysis patients in all hospitals 
affiliated to Golestan University of Medical Sciences. Standard infection prevention measures in hospital settings and 
dialysis units were performed including serologic testing for HCV antibody for every new patient in the dialysis unit as 
well as routine testing of all patients. Negative cases of hepatitis C antibody (confirmed with ELISA 2nd generation and 
RIBA II Immunoblot methods) were selected and followed for 18 months. Some predisposing factors such as 
transfusion, duration of hemodialysis, medical procedures including surgery, transplantation, invasive odontology, 
suspicious sexual contact, diagnostic or therapeutic manipulation, tattooing, and IV drug abuse, were registered and 
considered. Other rare procedures like acupuncture, manicure and pedicure, blood brotherhood rituals, perinatal risk 
factors, common circumcision rituals and history of abortion were also considered. We used a tight control policy 
through the separation of the rooms within the unit, specific hemodialysis apparatus for suspicious patients and a 
separate staff caring for the patients. We maintained a low rate of staff turnover in dialysis units and tried to control 
hepatitis B viral infection. 
Results: Marital status and living area were significantly related to HCV antibody positivity. It means that more HCV 
antibody positive cases were observed in married people in urban areas. History of tattooing, medical procedures 
including surgery, transplantation, invasive odontology and IV drug usage were not significantly related to HCV 
antibody status. During the follow up, three cases (4.3%) converted to positive. There was a relationship between 
numbers of hemodialysis per week and HCV antibody positivity (P<0.001). 
Conclusions: Tight control of transmission routes and severe isolation policy in this study explains an almost ideal 
decrease in incidence rate of HCV antibody positivity. We suggest periodical screening programs (at least every 6 
months) for blood samples that remain in the dialysis apparatus and all procedures used for hemodialysis in these 
specific patients to achieve a better infection control. 
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Hepatitis C1989 wh  virus (HCV) was first identified in en it was found to be the primary 
causative agent of non-A, non-B hepatitis, 
associated with high rates of progressive, end-stage 
liver disease. Since then, appreciation of the 
significant worldwide health impact of HCV 
infection has grown (1-4). HCV is mainly transmitted 
by blood transfusion. The introduction of routine 
screening for HCV in blood donors (1990) 
contributed significantly to the control of HCV 
transmission (4-7). The prevalence of HCV antibody 
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is high in patients undergoing hemodialysis (4, 8-13). 
From the one hand, nosocomial transmission of 
blood-borne pathogens is common in a dialysis 
setting and on the other hand, hepatitis C prevalence 
has a broad spectrum (9). Its prevalence is 5% in 
Western European countries and the United States 
and more than 20% in Mediterranean regions (14). 
Blood transfusion and the duration of hemodialysis 
are the most important factors in HCV transmission 
(11, 12, 15). Despite screening methods and use of 
erythropoietin for reducing blood transmission; 
these patients are at the risk of hepatitis C (2, 9, 15, 16). 
This study evaluated the appearance of anti-HCV 
antibody in hemodialysis patients and its 
relationship with demographic data such as marital 
status, domiciles and mean weekly hemodialysis. 
In this descriptive-analytical study which was 
conducted in 2005, all hemodialysis patients 
referred to the hospitals affiliated to Golestan 
University of Medical Sciences, northeast of Iran, 
who completed the written consents were recruited 
(93 hemodialysis). Standard infection prevention 
measures in hospital settings and dialysis units were 
performed including serologic testing for HCV 
antibody for every new patient in the dialysis unit as 
well as routine testing of all patients (e.g. CBC-Diff, 
Na, K, BUN and Cr). Negative cases of hepatitis C 
antibody (confirmed by ELISA 2nd generation and 
RIBA II Immunoblot methods) were selected and 
followed up for 18 months. 
Some predisposing factors such as transfusion, 
duration of hemodialysis, medical procedures 
including surgery, transplantation, invasive 
odontology, suspicious sexual contact, diagnostic or 
therapeutic manipulation, tattooing, and IV drug 
abuse were registered and considered. Other rare 
procedures like acupuncture, manicure and 
pedicure, blood brotherhood rituals, perinatal risk 
factors, common circumcision rituals, and history of 
abortion were considered as items in the 
questionnaires completed for each case. We used a 
tight control policy through the separation of the 
rooms within the unit, specific hemodialysis 
apparatus for suspicious patients and a separate staff 
caring for the patients. We maintained a low rate of 
staff turnover in dialysis units and tried to control 
hepatitis B viral infection. SPSS was used for data 
analysis and non-parametric and chi-square tests 
were applied for further analysis. 
Ninety-three patients with chronic renal failure 
enrolled in the study. Mean age was 47.37±15.91 
years. In these 93 hemodialysis patients, male to 
female ratio was 1:1 (Table 1). Seventy cases 
(75.3%) were HCV antibody negative (at the 
beginning) and were followed for 18 months. The 
 Table 1. Demographic data of hemodialysis patients
in Golestan province, Iran. 
Variables Numbers Percentage 
Gender 
Male 
Female 
51 
42 
54.8 
45.2 
Marital status 
Married 
Single 
74 
19 
79.6 
20.4 
Living area 
Urban 
Rural 
74 
19 
79.6 
20.4 
Household 35 37.63 
Office worker 7 7.52 
Student 1 1 
Job 
Jobless 
Retired 
15 
6 
16.12 
6.45 
Farmer 9 9.67 
Driver 4 4.3 
Worker 16 17.2 
Turkmen 15 16.1 
Ethnicity 
Fars 
Sistani 
71 
6 
76.3 
6.5 
Afghan 1 1.1 
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remaining 23 cases (24.7%) were HCV antibody 
positive at the beginning of the study (prevalence 
rate= 24.7%). Sex ratio, ethnicity and occupation 
were not significantly different between positive and 
negative cases (23 cases vs. 70 cases). 
Marital status and living area were significantly 
related to HCV antibody positivity in these 93 cases 
(P<0.05). It means that more HCV antibody 
positive cases were observed in married persons in 
urban areas. History of tattooing, Medical 
procedures including surgery, transplantation, 
invasive odontology and IV drug abuse were not 
significantly related to HCV antibody status. There 
was no difference between the prevalence of HBs 
antigen and HBs antibody at the beginning and at 
the end of our study. HCV antibody negative cases 
complained about icter more than antibody positive 
cases (P>0.05). 
History of transfusion was not significantly 
different between two groups, in other words, the 
number of blood units received by the patients was 
not statistically associated with the HCV-Ab 
prevalence; but the difference in mean weekly 
hemodialysis sessions was significant(P<0.05) (Table 
2). The mean duration of the hemodialysis (past 
history in years) was higher in HCV antibody 
positive cases (P<0.05) (Table 3). During the follow 
up period, among 70 negative cases, three of them 
(incidence rate=4.3%) turned to positive and were 
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 Table 2. Comparison of mean weekly hemodialysis
in patients with chronic renal failure according to
HCV antibody status. 
HCV antibody 
status 
Number of 
cases 
Mean hemodialysis 
number/week 
Standard 
deviation 
P value 
Positive 26 2.7 0.51 0.008 
Negative 67 2.3 0.54 
 Table 3. Comparison of hemodialysis duration (year)
in patients with chronic renal failure according to
HCV antibody status, Golestan province, Iran. 
HCV antibody 
status 
Number of 
cases 
Mean duration of 
hemodialysis (yr) 
Standard 
deviation 
P value 
Positive 26 9.91 5.72 0.001 
Negative 67 1.9 2.3 
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confirmed by Immunoblot method. HCV risk 
factors were not different among these three cases 
and others. To summarize, in comparison between 
26 positive cases and 67 negative cases at the end of 
the study, there were significant differences in 
marital status, living area, duration of dialysis (year) 
and mean weekly hemodialysis sessions (P<0.05). 
Approximately 200 million people are infected by 
HCV in the world. The main transmission route of 
HCV is parenteral (11, 17, 18). However, nearly 10% 
of the cases are sporadic, without well-defined 
transmission routes (19). Affected individuals are 
mostly patients who undergo multiple blood 
transfusions, intravenous and inhalant drug users, 
hemophiliacs, and hemodialysis patients (11, 19, 20). 
Blood-borne hepatitis is one of the major problems 
in hemodialysis centers (11, 21, 22). Several studies 
have been done to evaluate the routes of 
transmission and infection control in this 
population., In the year 1999, an increase in HCV 
antibody positive prevalence up to 39% and 19% 
were reported in the United States (11, 14, 23, 24) and 
in European countries (11), respectively. 
In this study, HCV antibody prevalence was 
24.7% (23 cases) at the beginning, and after 6­
month follow-up, the incidence rate was 4.3%. 
Prevalence data for patients submitted to 
hemodialysis vary in different regions (12, 25-27). In 
Japan, the prevalence of HCV antibody was 0.4­
3.3% in the general population and 9.1-51.6% in 
hemodialysis patients (11, 24, 28). In a study of four 
hemodialysis units in Venezuela, alarming 
prevalence and incidence rates of HCV were 
reported. The observed prevalence rate was 71% and 
the incidence rate was 38% (11), much higher than 
our results. Our results showed a prevalence rate of 
24.7% but at the end of the follow-up, the incidence 
rate was much lower (4.3%) than other studies. 
Tight control of transmission routes and severe 
isolation policy in this study can explains this almost 
ideal decrease in the incidence rate of HCV 
antibody positivity. 
Marriage and living in urban areas were the two 
important risk factors of HCV infection in the 
present study. Sexual transmission, unprotected 
sexual habits and some other risky behaviors are 
among the possible explanation for this higher rate. 
In this study no risky behaviors such as suspicious 
sexual contact, diagnostic or therapeutic 
manipulation, tattooing and IV drug abuse were 
registered. No other rare procedures such as 
acupuncture, manicure and pedicure, blood 
brotherhood rituals, perinatal risk factors, common 
circumcision rituals, and history of abortion were 
reported either. On the other hand, these rare 
procedures had no role in our population. 
Number of transfusions was not significantly 
different between the two groups (HCV antibody 
positive cases versus negative ones), but the 
difference in average weekly hemodialysis sessions 
between two groups was significant (P<0.05). 
The mean duration of hemodialysis was higher in 
HCV antibody positive cases, too (P<0.05). In 
reports of studies in Peru and Lyon, France, in 2005; 
it was shown that the number of transfusions and 
the duration of hemodialysis affect the infection rate 
in hemodialysis patients and the increase in the 
duration of hemodialysis (expressed as year) is 
associated with a higher prevalence in infection rate 
(9, 12). But nowadays, because of new screening 
methods, the role of transfusion is much lower than 
the past. Maybe the environment itself acts as a 
factor in dissemination of the virus in patients in 
hemodialysis centers (11). It has been shown that the 
duration of hemodialysis and frequent hemodialysis 
unit changes lead to more incidences of HCV 
infections (9, 29). Despite all preventive methods 
used in our study, 3 new cases were detected at the 
end of investigation. Nosocomial transmission can 
explain this result. Although our results were lower 
than other studies in Tunisia, Peru and India (2, 9, 27); 
the lower rate was expected due to the policy used in 
the study. 
Some epidemiological investigations have 
suggested nosocomial transmission via medical 
and/or nursing staff (30). It was considered in out 
control policy. New molecular and phylogenetic 
methods can detect the evidence for this route of 
transmission (2, 30). Lower incidence rates were 
observed in the centers that separate patients who 
are positive for anti-HCV antibody and in those 
that use separate rooms for the reutilization of the 
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dialyzers (11). It is concerned that immunodeficiency 
in patients with chronic renal failure, blood 
transfusion and invasive procedures are the main 
factors in the dissemination of this agent (22). Some 
interesting results remain unexplained in this study; 
for example the higher rate of icter in those who 
were HCV-Ab negative. We could not find any 
explanations for this, but it can suggest routine 
checking of Bilirubin, as well as liver function tests, 
in all hemodialysis patients. It has been shown that 
monthly testing of liver function test (LFT) besides 
antibody testing can identify the new cases more 
rapidly (31). 
It can be concluded that when chronic 
hemodialysis patients require dialysis while 
hospitalized, their infection status should be 
reviewed, and no instrument, supplies, or 
medications should be shared among them. For 
example, in our study a periodical control of HBV 
was done and no new cases of HBV infection were 
reported. Tight control of transmission routes and 
severe isolation policy in this study explains an 
almost ideal decrease in incidence rate of HCV 
antibody positivity. We suggest periodical screening 
programs (at least every 6 months) and accurate tests 
such as PCR in blood samples that remain in the 
dialysis apparatus and all procedures used for 
hemodialysis in these specific patients to achieve a 
better infection control. They should include 
implementation of new methodologies and 
infrastructure improvement of the centers; these 
measures could help improve the quality of life in 
hemodialysis patients. As there is a high risk of 
indirect and direct transmission of infectious agents 
in chronic hemodialysis, the vigilant observation of 
guidelines on universal precaution and regular 
virologic testing are the cornerstones of the effective 
control of chronic hepatitis in the hemodialysis 
settings. More studies could be helpful to find the 
best methods for the implementation of preventive 
and control measures of infection in chronic renal 
patients. 
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